MUMBAI, India, Jan. 2 -- Intellectual Property India has published a patent application (202511103010 A) filed by Dit University, Dehradun, Uttarakhand, on Oct. 2, 2025, for 'a podophyllotoxin-loaded folic acid chitosan nanoparticle sustained-release nanoparticle formulation and method for its preparation.'

Inventor(s) include Miss Darishalin Mawrie; Mr. Kangkan Sarma; Dr. Pankaj Pant; Dr. Santosh Kumar Rath; and Dr. Ashok Behera.

The application for the patent was published on Dec. 12, under issue no. 50/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to a sustained-release nanoparticle formulation (100) comprising podophyllotoxin (101) encapsulated within folic acid-conjugated chitosan nanoparticles (102) is disclosed. The formulation includes 0.5-10 wt% of podophyllotoxin (101) as the active therapeutic agent, 50-85 wt% chitosan nanoparticles (102) serving as a biocompatible polymeric carrier, and 0.5-5 wt% folic acid (103) conjugated to the nanoparticle surface to enhance targeted delivery. The nanoparticles (102) exhibit a particle size range of 50-250 nm, an encapsulation efficiency of 70-95%, and provide sustained release of podophyllotoxin (101) over a period of 12-72 hours. A method for preparing the formulation (100) is also disclosed, including: isolation of podophyllotoxin (101) from Podophyllum emodi roots via Soxhlet extraction and column chromatography; preparation of a chitosan solution (104); formation of chitosan nanoparticles (102) by ionic gelation with sodium tripolyphosphate (105); conjugation of folic acid (103) to the nanoparticles using EDC/NHS coupling chemistry (106); and encapsulation of podophyllotoxin (101) into the folic acid-conjugated chitosan nanoparticles (107). The process optionally includes sonication (108) at 30-60% amplitude for 5-15 minutes to reduce particle size, and freeze-drying (109) with 2-5% mannitol to obtain a stable nanoparticle powder. The formulation (100) enables targeted delivery for anticancer applications, with enhanced bioavailability and controlled drug release. to 22."

Disclaimer: Curated by HT Syndication.